Mavupharma

5400 Carillon Point
Building 5000 4th Floor
Kirkland
Washington
98003
United States

Show jobs for this employer

About Mavupharma

Mavupharma is a drug discovery and development company focused on novel approaches to selectively targeting the STING pathway, leveraging the innate immune system to treat cancer and infectious diseases. Mavupharma recently completed a $20 million Series A financing led by Frazier Healthcare Partners.

YEAR FOUNDED:
2016

LEADERSHIP:
President: Michael Gallatin, Ph.D.
CSO: Greg Dietsch, Ph.D., DABT
COO: Clayton D. Knox, M.D.

3 articles with Mavupharma